Oxaliplatin for Pretreated Patients with Advanced or Metastatic Pancreatic Cancer: A Multicenter Phase II Study

References

• Tominaga, S.; Kuroishi, T. Epidemiology of pancreatic cancer. Sem. Surg. Oncol. 1998, 15, 3–7. [CSA]
   PubMed Web of Science ®Google Scholar
• Barkin, J S.; Goldstein, J A. Diagnostic and therapeutic approach to pancreatic cancer. Biomed. Pharmacother. 2000, 54, 400–409. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hawes, R H.; Xiong, Q.; Waxman, I.; Chang, K J.; Evans, D B.; Abbruzzese, J L. A multispecialty approach to the diagnosis and management of pancreatic cancer. Am. J. Gastroenterol. 2000, 95, 17–31. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Burris, H A.; Moore, M J.; Andersen, J.; Green, M R.; Rothenberg, M L.; Modiano, M R.; Cripps, M C.; Portenoy, R K.; Storniolo, A M.; Tarassoff, P.; Nelson, R.; Dorr, F A.; Stephens, C D.; Von Hoff, D D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15, 2403–2413. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Glimelius, B.; Hoffman, K.; Sjoeden, P O.; Jacobsson, G.; Sellstrom, H.; Enander, L K.; Linne, T.; Svensson, C. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann. Oncol. 1996, 7, 593–600. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Palmer, K R.; Kerr, M.; Knowles, G.; Cull, A.; Carter, D C.; Leonard, R C. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br. J. Surg. 1994, 8, 882–885.
   Google Scholar
• Raymond, E.; Lawrence, R.; Izbicka, E.; Faivre, S.; Von Hoff, D D. Activity of oxaliplatin against human tumour colony-forming units. Clin. Cancer Res. 1998, 4, 1021–1029. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kornmann, M.; Fakler, H.; Butzer, U.; Beger, H G.; Link, K H. Oxaliplatin exerts potent in vitro cytotoxicity in colorectal and pancreatic cancer cell lines and liver metastases. Anticancer Res. 2000, 20, 3259–3264. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Rougier, P.; Ducreux, M.; Kaci, M O.; Boige, V.; Mitry, E.; Seitz, J F.; Bugat, R.; Breau, J L.; Etienne, P L.; Bouche, O.; Cvitkovic, E.; Bexon, A. Randomized phase III study of oxaliplatin alone (OXA), 5-fluorouracil (5-FU) alone, and the two drugs combined (OXA_Fu) in advanced or metastatic pancreatic adenocarcinoma. Proc. Am. Soc. Clin. Oncol. 2000, 19, 262a
   Google Scholar
• Fink, D.; Nebel, S.; Aebi, S.; Zheng, H.; Cenni, B.; Nehme, A.; Christen, R D.; Howell, S B. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 1996, 56, 4881–4886. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Brentnall, T A.; Chen, R.; Lee, J G.; Kimmey, M B.; Bronner, M P.; Haggitt, R C.; Kowdley, K V.; Hecker, L M.; Byrd, D R. Microsatellite instability and k-ras mutations associated with pancreatic adenocarcinoma and pancreatitis. Cancer Res. 1995, 55, 4264–4267. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Guidelines for Reporting Adverse Drug Reactions; Division of Cancer Treatment, National Cancer Institute: Bethesda, MD, 1978
   Google Scholar
• World Health Organization. Handbook for Reporting Results of Cancer Treatment; WHO Offset Publication No. 48, World Health Organization: Geneva, 1979
   Google Scholar
• Fleming, T. One sample multiple testing procedure for phase II clinical trials. Biometrics 1982, 38, 143–152. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Klein, B.; Sadikov, E.; Mishaeli, M.; Levin, I.; Fige, A. Comparison of 5-FU and leucovorin to gemcitabine in the treatment of pancreatic cancer. Oncol. Rep. 2000, 7, 875–877. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Louvet, C.; Andre, T.; Lledo, G.; Hammel, P.; Bleiberg, H.; Bouleuc, C.; Gamelin, E.; Flesch, M.; Cvitkovic, E.; de Gramont, A. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J. Clin. Oncol. 2002, 20, 1518–1521.
   Google Scholar
• Garnier, C.; Rebischung, C.; Chirpaz, E.; Baioso, J.; Fournet, J.; Pasquier, D.; Khayat, D.; Esterni, J.; Schaerer, R.; Mousseau, M. Phase II study of a combination with leucovorin (LV), 5-FU bolus and infusion (FU), gemcitabine (GEM) and oxaliplatin (L-OHP) (FOLFU GEMOX regimen) in locally advanced (LA) and metastatic (M) pancreatic carcinoma (APC). Proc. Am. Soc. Clin. Oncol. 2001, 20, 156a
   Google Scholar
• Alberts, S R.; Townley, P M.; Goldberg, R M.; Cha, S S.; Moore, D F., Jr.; Krook, J E.; Pitot, H C.; Fitch, T R.; Wiesenfeld, M.; Mailliard, J A.; Sargent, D J. Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study. Ann. Oncol. 2002, 13, 553–557. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Conroy, T.; Paillot, B.; Francois, E.; Rixe, O.; Bugat, R.; Jacob, J H.; Metges, J P.; Nasca, S.; Hua, A. Irinotecan (CPT-11), oxaliplatin (L-OHP), plus 5-FU/leucovorin (5-FU/LV) as first-line chemotherapy in patients (pts) with advanced pancreatic adenocarcinoma (APA). Proc. Am. Soc. Clin. Oncol. 2002, 21, 147a
   Google Scholar
• Pelzer, U.; Hempel, C.; Stieler, J.; Köneke, D.; Riess, H.; Oettle, H. Oxaliplatin (OXA) in combination with high dose 5-FU (24 h)/folinic acid (FA) as salvage therapy in patients with gemzar-refractory advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 2002, 21, 172a
   Google Scholar
• Cantore, M.; Rabbi, C.; Cavazzini, G.; Ogliani, C.; Aitini, E. Irinotecan and oxaliplatin combination therapy in patients with advanced pre-treated pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 2002, 21, 96b
   Google Scholar
• Faivre, S.; Raymond, E.; Woynarowski, J M.; Cvitkovic, E. Suppraadditive effect of 2′2′-diflurodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother. Pharmacol. 1999, 44, 117–123. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Raymond, E.; Buguet-Fagot, C.; Djelloul, S.; Mester, J.; Cvitkovic, E.; Allain, P.; Louvet, C.; Gespach, C. Antitumour activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancer. Anticancer Drugs 1997, 8, 876–885. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Van Cutsem, E.; Karasek, P.; Oettle, H.; Vervenne, A.; Szawlowski, P.; Schoffski, S.; Post, H.; Neumann, H.; Safran, Y.; Humblet, H.; van de Velde, Y.; Ma, D. Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC). Proc. Am. Soc. Clin. Oncol. 2002, 21, 130a
   Google Scholar